Meet the Minds Behind the Mission
A dedicated team of experts driving the battle against cancer, fueled by a passion for innovation and a profound commitment to improve patient's care.
Executive leadership
A PharmD and ESSEC graduate with extensive expertise in pharma development and business strategy. He has oncology experience from roles at Abbott and Roche and has worked in M&A at Juvisé. He later moved to venture capital at Truffle Capital, where he supported biotech startups and secured strategic
Philippe Karoyan, Professor at the Laboratoire de Biomolécules (Sorbonne Université, CNRS, ENS) and Head of DRUGLab, is an expert in therapeutic peptides with 6 related patents, including those for PepKon. His research focuses on innovative cancer peptide therapies.
.png)
With over 20 years in preclinical research, she began as a Study Director at MDS Pharma and CiToxLab. She contributed to drug development at Alizé Pharma. After managing veterinary services at Porsolt, she led animal health at Inovalys and LDA53. Now, she is PepKon’s preclinical specialist.
With a dual PhD from Universidad Autónoma de Nuevo León and Sorbonne Université, he began researching cancer biology in 2017. At Sorbonne, he gained expertise in peptide design under Philippe Karoyan. In 2022, he joined PepKon and is now Scientific Project Manager.
Consultants & advisors
With a PhD from the Faculté de Médecine de Paris, he has 30 years of experience in drug and cosmetic development. He led Cellpep/Ambrilia as CEO/CSO and was COO and CEO at Peptigroupe Inc. Now, as Preclinical Development Advisor at PepKon, he brings expertise in preclinical drug development
With 23 years of experience in the pharmaceutical industry, she has held key positions such as CDMO Site Director, Pharma Development Consultant, COO, and Auditor of pharma and lab sites. As the founder of Inits, she established a consultancy specializing in pharmaceutical development, offering expert guidance to biotech and pharma companies. Amel supports PepKon in the CMC (Chemistry, Manufacturing, and Controls) domain.
A graduate of the Faculty of Pharmacy of Montpellier, she held roles in pharmaceutical labs and CROs, managed a biotech portfolio for a private fund, and founded ILife Consulting, a European CRO. She supports PepKon’s clinical plan optimization.
With a Doctorate of Veterinary Medicine and a Ph.D. in Physiology, he is a seasoned toxicologist and former President of the French Society of Toxicology. He has extensive CRO experience, contributed to drug and vaccine approvals, and chaired the Animal Ethics Committee. Since 2020, he is a Toxiclogy Expert.
She holds an MSc in Molecular and Cellular Biology and a PhD in Immunology. After starting at Cabinet Plasseraud in Biotech, she co-founded ICOSA specializing in Biotech IP. As a European Patent Attorney, she manages patent portfolios and advises on IP strategy. Claire supports PepKon's IP strategy.
Board of directors
She is a PharmD and MBA graduate of HEC Paris with experience as a hospital pharmacist and in the pharma industry. She founded the APHP Technology Transfer Office, creating over 75 health startups. She co-founded SparingVision and raised €130M. Now, she chairs PepKon’s Executive Committee and advises on R&D strategy.
A Polytechnique and ENA graduate, he is an entrepreneur and investor with CEO experience at Vivendi. Since 2017, he has focused on biotechnology, founding companies and launching Sorbonne Ventures. He was PepKon’s Managing Director and now serves as Chairman.
SAB, medical advisors
A leading hematologist with expertise in CLL and lymphomas, she led the Hematology Department at Pitié-Salpêtrière Hospital and contributed significantly to blood cancer research. Dr. Leblond, active in key hematology organizations, supports PepKon’s CLL work.
A hematologist and professor at the University of Paris-Saclay, he is a former Director of Research at Gustave Roussy and founded Inserm units on cell death and cancer. His CMML research has resulted in 350+ publications. Dr. Solary, a 2018 Raymond-Rosen Prize recipient, collaborates with PepKon on CMML.
She holds an MD and PhD and is Director of the CLL Center at Dana-Farber Cancer Institute and Professor at Harvard Medical School. Renowned for her research on CLL genomics, which has led to over 150 publications, she is a leading CLL expert and a sought-after international speaker.
He is a Senior Hematologist and Professor at the University of Toulouse, leading B-cell lymphoma studies and researching lymphoma immunotherapies and tumor resistance. A member of LYSA and FiLO-LLC, he collaborates with PepKon on CLL.